Bai J J, Zhang W L, Wang L, Liu P Y, Cai J
Hypertension Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China.
State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100037, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2021 Oct 24;49(10):993-999. doi: 10.3760/cma.j.cn112148-20201231-01022.
Explore the usage of anti-hypertension drugs and the rationality of hypertension prescription among the primary health centers in Dongcheng District, Beijing. This cross-sectional and retrospective study was applied to analyze the hypertension prescriptions from the 8 community health centers in Dongcheng District. The anatomical, therapeutic and chemical classification (ATC) codes were used to determine the drug category. ATC information was used to filter data containing antihypertensive drugs, and group the number and proportion of ATC categories. The type of drug was judged by its generic name. According to the diagnosis information in the prescription, the prescription containing the Western medicine diagnosis of hypertension was screened out. The comorbidities of hypertension in the study included 7 types of diseases including diabetes, chronic kidney disease, coronary heart disease, heart failure, atrial fibrillation, stroke, and dyslipidemia. The analysis of prescription rationality included rationality of combination medication, rationality of drug dosage and rationality of drug price. The agreed daily dose (DDD) method was used to analyze the rationality of drug dosage. The drug utilization index (DUI) was used as a quantitative indicator to estimate the rationality of medication, and overdose was expressed by DUI>1. The reasonableness of the drug price was judged based on the price of the drug and whether it was a drug in the "4+7" plan. A total of 658 140 prescriptions were extracted as the final data set, involving 7 categories and 60 commonly used anti-hypertensive drugs, and the corresponding cost of medication was ¥96.58 million. Drugs were prescribed according to comorbidities, and the choice followed the international guidelines. Calcium channel blockers (CCB) were the most prescribed drugs in the prescriptions of patients with comorbidities, and α-adrenergic receptor antagonists were the least prescribed drugs. The proportion of diuretics prescribed in hypertensive patients complicating with heart failure was 21.17% (505/2 385), which was much higher than that of patients complicating with other comorbidities (<0.05). The proportion of diuretics prescribed in hypertension patients complicating with dyslipidemia was lower than that of patients with other comorbidities (2 639 (0.94%), <0.05), and β-blockers (BB) or angiotensin Ⅱreceptor blockers (ARB) were more likely to be selected (BB: 59 348 (21.08%), ARB: 51 356 (18.24%))in these patients. The proportion of BB in prescriptions for hypertension patients with chronic kidney disease was lower than that of patients with other comorbidities (<0.05). The proportion of BB in prescriptions for hypertension patients with coronary heart disease was higher than that of other comorbidities (<0.05). Hypertension patients with atrial fibrillation or stroke accounted for a higher proportion of CCB prescriptions (<0.05). Single antihypertensive drug prescriptions accounted for the highest proportion, 61.19% (402 745/658 140). Two-combination prescriptions accounted for the highest proportion of combination prescriptions, 72.19% (184 392/255 395). CCB based two-combination prescriptions accounted for the highest proportion, 122 350(66.36%). ARB-based tri-combination prescriptions accounted for the highest proportion, 48 915(89.50%),followed by CCB based tri-combination prescriptions (44 732(81.85%)).There were 2 174 (0.33%) prescriptions with unreasonable combination therapies and DUI>1 were found in 48 out of 60 commonly used drugs. In all possible antihypertensive drugs, only 40.92% (109 227/266 993)followed the "4+7" plan. The anti-hypertensive agents from these prescriptions in the primary health centers are diverse, and the choice is generally complied with the guidelines, but some unreasonable situations existed, especially on the combined anti-hypertensive medication, overdose, and"4+7"plan is not followed completely.
探索北京市东城区基层医疗卫生机构抗高血压药物的使用情况及高血压处方的合理性。本横断面回顾性研究对东城区8家社区卫生服务中心的高血压处方进行分析。采用解剖学、治疗学及化学分类(ATC)代码确定药物类别。利用ATC信息筛选出含抗高血压药物的数据,并对ATC类别数量及比例进行分组。通过通用名判断药物类型。根据处方中的诊断信息,筛选出含高血压西医诊断的处方。本研究中高血压的合并症包括糖尿病、慢性肾脏病、冠心病、心力衰竭、心房颤动、脑卒中、血脂异常7种疾病。处方合理性分析包括联合用药合理性、药物剂量合理性及药物价格合理性。采用限定日剂量(DDD)法分析药物剂量合理性。用药频度(DUI)作为定量指标评估用药合理性,DUI>1表示用药过量。根据药物价格及是否为“4+7”带量采购药品判断药物价格合理性。共提取658140张处方作为最终数据集,涉及7类60种常用抗高血压药物,相应用药费用为9658万元。根据合并症开具药物,选择遵循国际指南。合并症患者处方中,钙通道阻滞剂(CCB)为最常用药物,α-肾上腺素能受体拮抗剂为最不常用药物。高血压合并心力衰竭患者中,利尿剂处方比例为21.17%(505/2385),远高于合并其他合并症患者(<0.05)。高血压合并血脂异常患者中,利尿剂处方比例低于合并其他合并症患者(2639例(0.94%),<0.05),这些患者更倾向于选择β受体阻滞剂(BB)或血管紧张素Ⅱ受体拮抗剂(ARB)(BB:59348例(21.08%),ARB:51356例(18.24%)))。高血压合并慢性肾脏病患者处方中BB比例低于合并其他合并症患者(<0.05)。高血压合并冠心病患者处方中BB比例高于其他合并症患者(<0.05)。心房颤动或脑卒中高血压患者CCB处方比例较高(<0.05)。单药抗高血压处方占比最高,为61.19%(402745/658140)。两药联合处方在联合处方中占比最高,为72.19%(184392/255395)。以CCB为基础的两药联合处方占比最高,为122350例(66.36%)。以ARB为基础的三药联合处方占比最高,为48915例(89.50%),其次是以CCB为基础的三药联合处方(44732例(81.85%))。发现217例(0.33%)联合治疗不合理的处方,60种常用药物中有48种存在DUI>1的情况。在所有可能的抗高血压药物中,仅40.92%(109227/26699三)遵循“4+7”带量采购计划。基层医疗卫生机构这些处方中的抗高血压药物种类多样,选择总体遵循指南,但存在一些不合理情况,尤其是联合抗高血压用药、用药过量以及未完全遵循“4+7”带量采购计划等问题。